3-D Matrix's First Profitable Year Wasn't What It Looked Like

3-D Matrix reported its first-ever full-year profit in fiscal 2026. Revenue nearly doubled. Net income jumped to 4.2 billion yen. The stock surged to 793 yen — a 52-week high — and for a few weeks, the narrative was simple: a small Japanese meddevice company had finally crossed the line from money-losing biotech startup to profitable growth business.

Then the details arrived.

Behind that headline net income sat a 2.0 billion yen foreign exchange gain — accounting profit from yen depreciation applied to foreign-currency assets. No cash actually moved. The company's own president called it exactly that and told investors to look at operating profit instead. Operating profit for the full year was 1.3 billion yen, on a 12% margin. Not bad, but very different from the 38% net margin the headline implied.

Then came the first quarter of the new fiscal year — May through July 2026. Revenue grew another 47%, to 3.2 billion yen. Ordinary profit fell 64%. The market's response was sharp: the stock dropped more than half from its peak to the 360-380 yen range where it trades today.

Here's what's actually going on, and what it means for the investment case.

The real profit picture

Fiscal year 2026 ended in April 2026. On a 10.9 billion yen revenue base, 3-D Matrix generated:

• Gross profit: 8.6 billion yen (79% margin)
• Operating profit: 1.3 billion yen (12% margin)
• Net income: 4.2 billion yen (38% margin) — but roughly half of that was the FX windfall

The gross margin recovery is real and meaningful. It had been suppressed to 64% in the prior year by product valuation losses and raw material write-downs. At 79%, it reflects the underlying economics of the self-assembling peptide technology that powers their hemostatic gel products, led by PuraStat — a stop-the-bleeding agent used in gastrointestinal endoscopy procedures. The product works, surgeons use it, and the margins on it are genuinely high.

Operating margin at 12% is the number that actually represents how well the business runs. It's solid for a company this small — just 129 employees — growing revenue at nearly 60%, and still investing in sales infrastructure abroad.

The FX gain is the number that inflated everything else. When you strip it out, ordinary profit drops roughly in half and the net income figure looks nothing like the headline. The company warned about this explicitly: if the yen strengthens, that one-time gain disappears and could reverse. That warning was specific and credible because they chose foreign-currency loans to subsidiaries as their funding mechanism, which naturally creates these accounting swings.

What Q1 tells us

The first quarter of fiscal 2027 (May-July 2026) is the first real test without the FX mask. Revenue jumped 47% year-over-year to 3.2 billion yen. The business is clearly still growing — the US market, which accounts for about 58% of total revenue, continues to add customers in the gastroenterology space.

But ordinary profit fell 64%. That's the margin squeeze the headline flagged, and it's not surprising once you understand the math. When last year's first quarter benefited from a proportional share of that FX windfall, this year's quarter has to stand on operating margins alone. A 12% operating margin on a growing base is real profit — it's just not the inflated profit that the full-year headline suggested.

This is the kind of divergence that matters. Revenue growth of 47% on a small base is impressive. A 64% profit decline on a base that included a one-time accounting gain is not. The two facts aren't contradictory; they tell you what the business is actually doing and what it was doing when the accounting coincided in its favor.

The free cash flow question

This is where the story gets interesting, and where you need to look past both the revenue excitement and the margin disappointment.

For fiscal 2026, 3-D Matrix generated 369 million yen in free cash flow — operating cash flow of 396 million yen minus 27 million yen in capital expenditures. That's its first positive FCF year after years of burning through cash. The prior year saw an operating cash flow deficit of 1.7 billion yen and a free cash flow hole of the same size.

A 369 million yen number on a 10.9 billion yen revenue base gives you an FCF margin of about 3.4%. That's thin. But it's positive, it's new, and it's the first evidence that this business can actually generate cash after covering its operating costs and capital needs. The balance sheet repair is even more striking: total debt fell from 2.9 billion yen to 600 million yen as convertible bonds were fully converted, and the company now sits on a net cash position of roughly 1.1 billion yen.

The accrual ratio — a measure of how much reported earnings were backed by actual cash — was 0.93 for the year ending April 2026. That means the company didn't generate anywhere near enough cash flow to match its reported earnings. The number is high because the FX gain inflated earnings without creating corresponding cash. Strip the FX out, and the accrual ratio looks much more reasonable for a company this early in its profitability journey.

What matters going forward is whether free cash flow scales with revenue. The company is guiding for 13.4 billion yen in revenue next fiscal year — a 23% increase — with operating profit of 1.6 billion yen and operating margins holding around 12%. If that materializes and capex stays contained, the FCF trajectory should be meaningfully higher. The question isn't whether the business is broken; it's whether a 12% operating margin on a high-growth revenue base can reliably convert to cash at an accelerating rate.

The stock price did the hard work

The stock's decline from 793 yen to the current 360-380 yen range matters more than any single earnings release. At the peak, investors were pricing 3-D Matrix as a high-growth meddevice compounder about to sustain rapid margin expansion. The full-year net income of 4.2 billion yen — inflated by a 2.0 billion yen FX gain — made the math look like it supported that view. But on an operating basis, stripping out that currency tailwind, the earnings multiple at 793 yen was still well above what a company with a 12% operating margin and 3.4% free cash flow margin typically commands.

At current levels, the same operating earnings base gives a P/E that's fallen roughly in half. That's a number that starts to look like a growth company with proven revenue momentum and early cash generation, rather than a biotech turnaround that the market had temporarily overexcited itself about.

What would prove this right or wrong

The US market is the engine — 6.3 billion yen in FY2026, growing 77% year-over-year through expanding gastroenterology adoption and a shift to in-house sales that preserves high gross margins. The company is guiding for 8.5 billion yen in US revenue next year, a 37% increase. If that growth rate holds or accelerates, the revenue trajectory is intact and the margin question is mostly about how fast operating leverage kicks in.

The bear case is straightforward. If US adoption slows — whether from competition from larger players like Baxter, Ethicon, or Merit Medical, or from pricing pressure — the entire growth story compresses. More than half the company's revenue comes from one market. There's also the Japan market, which is essentially flat and under pressure from insurance claim rejections that have made hospitals cautious about purchasing. And the share structure: the company has issued MS warrants — instruments that dilute existing shareholders — no fewer than 10 times over the past decade. That's a pattern that signals capital constraints and creates a persistent overhang on the stock.

The specific thing that would break this thesis: US revenue growth falling well below the 25-30% range while operating margins stagnate or decline. That would tell you the product has hit a ceiling in its primary market and the operating leverage story isn't arriving. Conversely, the thing that would confirm it: free cash flow doubling or tripling in the next fiscal year, showing that the 12% operating margin is real, sustainable, and converting to cash at an improving rate.

The actual setup right now

This isn't a company where the numbers are great but the stock is depressed for no reason. The stock fell because the earnings headline was misleading and the market correctly reassessed what 3-D Matrix actually earns. But the correction overshot from a multiple built on inflated headline earnings to one that's now in the normal range for a company with this growth profile and these margins.

The operating setup is cleaner than it was a year ago: gross margins have recovered to their structural level, the company is profitable on an operating basis, free cash flow has turned positive, and the balance sheet is in shape. The revenue trajectory is steep. The margin question — whether 12% expands toward the 15-20% range the market has speculated about — is genuinely open and will be answered by the next two quarters of results.

The business has real product-market fit in the US hemostatic gel market, proven at the operating level, not just the revenue level. That's more than most small meddevice companies at this stage can claim. The risk is concentration: one product platform, one dominant market, one growth curve. If that curve bends, there's no second act ready to step in.